Barely Significant
← all excerpts

Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma.

Front Immunol · 2024 · PMC11537909 · PMID 39507533

1
hedged sentence
closest p
boldest claim

The sentences

showed a trendno p-value reported
The PFS rates at 6, 12, and 18 months in the HPL group were 82.1%, 43.4%, and 31.2%, respectively, The PFS rate of the HDL group showed a trend of being superior to the HPL group, but there was still no statistically significant difference.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.